Physician profile
Robert Cazayoux
NPI 1013018548
$1,554.69
in general payments reported to CMS, 2019-2025
18 companies · $71.68 in 2025
The $71.68 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $97.90 · 2021: $215 · 2022: $453 · 2023: $175 · 2024: $411 · 2025: $71.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $657.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $366.56 | 2019-2023 | Liletta |
| Smith+Nephew, INC. | $228.32 | 2020-2024 | Stravix, Grafix, Renasys Go V2 Home |
| Organogenesis INC. | $152.26 | 2021-2024 | |
| Convatec INC. | $147.18 | 2022-2023 | |
| Hydrofera LLC | $111.29 | 2024 | Hydrofera Blue |
| Organon LLC | $99.98 | 2022-2024 | Nexplanon |
| Mylan Pharmaceuticals INC. | $94.08 | 2019-2022 | |
| Astellas Pharma US INC | $85.06 | 2023-2025 | Veozah |
| Pfizer INC. | $68.91 | 2019-2024 | |
| Hologic Sales and Service, LLC | $66.73 | 2021-2023 | Aptima |
| Merck Sharp & Dohme LLC | $31.97 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $17.38 | 2024 | |
| Coloplast Corp | $16.97 | 2019 | |
| Amgen INC. | $16.32 | 2019 | |
| Myovant Sciences INC. | $15.94 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $13.14 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $11.70 | 2019 | |
| Mallinckrodt Enterprises LLC | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cazayoux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.